Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgkin's LymphomasBusiness Wire • 06/26/23
Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid TumorsBusiness Wire • 06/12/23
Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld UniversityBusiness Wire • 06/08/23
Lantern Pharma to Present at the Lytham Partners Spring 2023 Investor Conference Thursday, May 18th at 9:00 a.m. ETBusiness Wire • 05/17/23
Lantern Pharma Reports First Quarter 2023 Financial Results and Operational HighlightsBusiness Wire • 05/09/23
Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical TrialPRNewsWire • 05/03/23
Lantern Pharma to Report First Quarter 2023 Operating & Financial Results on May 9, 2023 at 4:30 p.m. ETBusiness Wire • 05/02/23
Lantern Pharma Develops Top-Ranked AI Algorithms to Predict the Blood-Brain-Barrier Permeability of Any CompoundBusiness Wire • 05/02/23
Lantern Pharma Receives Notice of Allowance for Composition of Matter Patent Covering Drug Candidate LP-284Business Wire • 04/13/23
Lantern Pharma Announces First Patient Dosed in the Phase 2 Study, Harmonic™, for LP-300 in Never Smokers with Advanced Non-Small Cell Lung CancerBusiness Wire • 03/28/23
Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational HighlightsBusiness Wire • 03/20/23
Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual MeetingBusiness Wire • 03/15/23
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2022 Operating & Financial Results on March 20, 2023 at 4:30 p.m. ETBusiness Wire • 03/13/23
Lantern Pharma said it had no exposure to SVB or Signature Bank, after stock plunged last weekMarket Watch • 03/13/23
Lantern Pharma Confirms It Had No Exposure to Silicon Valley Bank (SVB), Silvergate Bank, or Signature BankBusiness Wire • 03/13/23
Lantern Pharma Announces New Data and Development Focus for LP-100 with PARP InhibitorsBusiness Wire • 03/09/23
Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the Powerful Mechanism of Action Behind Several of Lantern's Drug Candidates, Featuring Zoltan Szallasi, M.D.Business Wire • 03/08/23
Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain CancersBusiness Wire • 03/06/23
Lantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing and Upcoming Clinical TrialsBusiness Wire • 03/02/23
Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352Business Wire • 02/27/23